Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials

Lockwood, Jonathan; Remington, Gary

doi:10.1517/14728214.2015.1050376

Cited by 14 publications

(6 citation statements)

References 123 publications

(119 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…130 These are potentially irreversible late onset repetitive abnormal involuntary movements primarily of the face and limbs. 126,[131][132][133][134] They occur in up to 30% of treated patients and may be debilitating and socially stigmatizing. The second-generation antipsychotics cause less tardive dyskinesia; however, it still develops at an annual incidence of 4%.…”

Section: Tardive Dyskinesiamentioning

confidence: 99%

Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders

Quik

Boyd

Bordia

et al. 2018

Nicotine &Amp; Tobacco Research

View full text Add to dashboard Cite

Accumulating data from preclinical studies and clinical trials suggest that drugs targeting CNS cholinergic systems may be useful for symptomatic treatment of movement disorders. Nicotinic cholinergic drugs, including nicotine and selective nAChR receptor agonists, reduce L-dopa-induced dyskinesias, as well as antipsychotic-induced tardive dyskinesia, and may be useful in Tourette's syndrome and ataxia. Subtype selective muscarinic cholinergic drugs may also provide effective therapies for Parkinson's disease, dyskinesias and dystonia. Continued studies/trials will help address this important issue.

show abstract

Section: Tardive Dyskinesiamentioning

confidence: 99%

Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders

Quik

Boyd

Bordia

et al. 2018

Nicotine &Amp; Tobacco Research

View full text Add to dashboard Cite

show abstract

“…The exact mechanism by which typical APDs result in the development of TD remains largely uncertain. However, the most compelling line of evidence suggests that chronic dopamine blockade caused by dopamine D2 receptor antagonists or APDs could result in an upregulation of dopamine receptor responsiveness, resulting in a compensatory supersensitivity of the receptors in the nigrostriatal pathway [30,31]. As shown in Table 4, chlorpromazine contains all of top ten substructures.…”

Section: Discussionmentioning

confidence: 99%

Relating Substructures and Side Effects of Drugs with Chemical-chemical Interactions

Zhou

Xian

Lü

et al. 2020

CCHTS

View full text Add to dashboard Cite

Background: Drugs are very important for human life because they can provide treatment, cure, prevention, or diagnosis of different diseases. However, they also cause side effects, which can increase the risks for humans and pharmaceuticals companies. It is essential to identify drug side effects in drug discovery. To date, lots of computational methods have been proposed to predict the side effects of drugs and most of them used the fact that similar drugs always have similar side effects. However, previous studies did not analyze which substructures are highly related to which kind of side effect. Method: In this study, we conducted a computational investigation. In this regard, we extracted a drug set for each side effect, which consisted of drugs having the side effect. Also, for each substructure, a set was constructed by picking up drugs owing such substructure. The relationship between one side effect and one substructure was evaluated based on linkages between drugs in their corresponding drug sets, resulting in an Es value. Then, the statistical significance of Es value was measured by a permutation test. Results and Conclusion: A number of highly related pairs of side effects and substructures were obtained and some were extensively analyzed to confirm the reliability of the results reported in this study.

show abstract

“…Being a typical anti-psychotic haloperidol (HP) have a strong a nity to bind with dopamine D 2 receptor. This mechanism causes supersensitivity in the postsynaptic striatal dopamine D 2 receptors, in uence MSN in indirect pathway, causing a wide range of side effects (facial jerking, vacuous chewing movements (VCM), cheek pu ng, eye blinking, tongue protrusion, and lip-smacking) and likely contributes to the repetitive involuntary (orofacial) movement and develops TD (Lockwood & Remington, 2015;Thakur et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Neuroprotective Effect of Filgrastim in Animal Models of 3-Nitropropionic Acid & Haloperidol Induced Neurotoxicity in Rats

Rahi¹,

Ram²,

Kumar³

2021

Preprint

View full text Add to dashboard Cite

Movement disorders are the heterogeneous group of disorders characterized by the progressive and selective impairment in motor function. Movement disorders like Huntington's disease (HD) and Tardive dyskinesia (TD) share many common features at both cellular and subcellular levels. Filgrastim is a recombinant methionyl granulocyte colony-stimulating factor (GCSF), shows neuroprotective properties in in-vivo models of movement disorders. The present study was designed to evaluate the neuroprotective effect of filgrastimin the animal models of haloperidol and 3-NP induced neurotoxicity in rats. Study was divided in two different protocol, in study one, rats were administered with haloperidol for 21 days, and filgrastim at the dose of (20, 40 & 60 µg/kg,s.c.) was administered once a day, before haloperidol treatment and the following parameters (orofacial movements, rotarod, actophotometer) were assessed for TD. Similarly, in second study rats were administered with 3-NP for 21 days and filgrastimat the dose of (20 & 40 µg/kg, s.c.) was administered, and following parameters (rotarod, narrow beam walk and open field test) were assessed for HD. In each study, on 22nd day, animals were sacrificed, to isolate cortex and striatum for oxidative stress (LPO, GSH, SOD, catalase, and nitrate) parameters. The result revealed that haloperidol and 3-NP treatment significantly impaired motor coordination, oxidative defense and induce TD and HD like symptoms. Filgrastim pre-treatment significantly averted haloperidol & 3-NP induced behavioral and biochemical alterations, respectively. Conclusively, neuroprotective effect of filgrastim is credited to its antioxidant properties, hence filgrastim might be a novel therapeutic candidate to manage TD & HD.

show abstract

Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials

Abstract: Effective adjunctive treatment for the symptoms of TD will depend on gaining a better understanding of the neurological changes induced by chronic dopamine D2 receptor antagonism from APs.

Cited by 14 publications

References 123 publications

Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders

Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders

Relating Substructures and Side Effects of Drugs with Chemical-chemical Interactions

Neuroprotective Effect of Filgrastim in Animal Models of 3-Nitropropionic Acid & Haloperidol Induced Neurotoxicity in Rats

Contact Info

Product

Resources

About

Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials

Abstract: Effective adjunctive treatment for the symptoms of TD will depend on gaining a better understanding of the neurological changes induced by chronic dopamine D2 receptor antagonism from APs.

Cited by 14 publications

References 123 publications

Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders

Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders

Relating Substructures and Side Effects of Drugs with Chemical-chemical Interactions

Neuroprotective Effect of Filgrastim in Animal Models of 3-Nitropropionic Acid &amp; Haloperidol Induced Neurotoxicity in Rats

Contact Info

Product

Resources

About

Neuroprotective Effect of Filgrastim in Animal Models of 3-Nitropropionic Acid & Haloperidol Induced Neurotoxicity in Rats